Citius Oncology (NASDAQ:CTOR) Trading Up 0.6% – Here’s What Happened

Citius Oncology, Inc. (NASDAQ:CTOR)’s stock price traded up 0.6% during trading on Wednesday . The company traded as high as $0.6298 and last traded at $0.5732. 116,917 shares were traded during mid-day trading, an increase of 110% from the average daily volume of 55,782 shares. The stock had previously closed at $0.57.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Citius Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.00.

Citius Oncology Price Performance

The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.12 and a current ratio of 0.50. The stock has a market capitalization of $53.30 million, a P/E ratio of -1.22 and a beta of 3.47. The firm has a 50-day moving average price of $0.73 and a 200 day moving average price of $0.87.

Citius Oncology (NASDAQ:CTOR) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.26). The company had revenue of $1.67 million during the quarter, compared to the consensus estimate of $7.00 million.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its holdings in shares of Citius Oncology by 5,256.9% in the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after acquiring an additional 8,411 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Citius Oncology by 49.5% during the 3rd quarter. IFP Advisors Inc now owns 33,215 shares of the company’s stock valued at $67,000 after purchasing an additional 11,000 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Citius Oncology during the 3rd quarter valued at $36,000. Geode Capital Management LLC grew its holdings in shares of Citius Oncology by 179.0% during the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after purchasing an additional 36,758 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp purchased a new position in Citius Oncology in the 4th quarter worth $104,000. 70.52% of the stock is owned by hedge funds and other institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.